N4 Pharma PLC (GB00BYW8QM32)
Market Closed
21 Aug, 20:00
XSTU 
LSE Primary XSTU €
0. 01
0
0%
€
- Market Cap
- P/E Ratio
72% Div Yield
60 Volume
- Eps
€ 0.01
Previous Close Want to track GB00BYW8QM32 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
GB00BYW8QM32 closed today higher at €0.01, an increase of 0% from yesterday's close, completing a monthly decrease of -6.6667% or €0. Over the past 12 months, GB00BYW8QM32 stock gained 600%.
GB00BYW8QM32 is not paying dividends to its shareholders.
The last earnings report, released on Sep 10, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
N4 Pharma PLC has completed 1 stock splits, with the recent split occurring on May 03, 2017.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on LSE (GBP).
GB00BYW8QM32 Chart
N4 Pharma PLC (GB00BYW8QM32) FAQ
What is the stock price today?
The current price is €0.01.
On which exchange is it traded?
N4 Pharma PLC is listed on XSTU.
What is its stock symbol?
The ticker symbol is GB00BYW8QM32.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 72%.
What is its market cap?
As of today, no market cap data is available.
Has N4 Pharma PLC ever had a stock split?
N4 Pharma PLC had 1 splits and the recent split was on May 03, 2017.
N4 Pharma PLC Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dr. David Horn Solomon M.D. CEO | XSTU Exchange | GB00BYW8QM32 ISIN |
| United Kingdom Country | 4 Employees | - Last Dividend | 3 May 2017 Last Split | - IPO Date |
Overview
N4 Pharma Plc is a distinguished specialist pharmaceutical company operating out of London, United Kingdom. Since its incorporation in 1979, the company has been at the forefront of developing innovative silica nanoparticle delivery systems. These advanced systems are designed to serve the pharmaceutical and biotechnology sectors within the UK, offering new possibilities in the delivery of therapeutics. N4 Pharma Plc is dedicated to revolutionizing the healthcare industry by providing cutting-edge solutions that enhance the efficacy and delivery of vaccines and cancer treatments.
Products and Services
- Nuvec - A groundbreaking non-viral adjuvant delivery system primarily aimed at enhancing the delivery of vaccines and cancer treatments. Nuvec is an innovative solution developed by N4 Pharma Plc to address the limitations of current delivery systems in the biopharmaceutical industry. By employing silica nanoparticles, Nuvec significantly improves the stability and efficiency of therapeutic delivery, ultimately leading to more effective treatment outcomes. It stands at the forefront of N4 Pharma's efforts to contribute to the advancement of medical science and patient care.
Contact Information
Address: 2 Portman Street
Phone: 44 20 4610 0714
Website: https://www.thaliatx.com
